Page 67 - Read Online
P. 67

Li et al. Hepatoma Res. 2026;12:36                                               Page 13 of 15



               Ethical approval and consent to participate
               Not applicable.

               Consent for publication
               Not applicable.

               Copyright
               © The Author(s) 2026.


               REFERENCES
               1.  Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36
                  cancers in 185 countries. CA Cancer J Clin. 2024;74:229-63. DOI PubMed
               2.  Liu CJ, Chen PJ. Changing epidemiology of liver disease in Asia: dual infection of HBV and HCV. Liver Int. 2022;42:1945-54. DOI
                  PubMed
               3.  Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol. 2021;75:1476-84. DOI PubMed
               4.  Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400:1345-62. DOI PubMed
               5.  European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J
                  Hepatol. 2025;82:315-74. DOI PubMed
               6.  Taddei TH, Brown DB, Yarchoan M, Mendiratta-Lala M, Llovet JM. Critical update: AASLD Practice Guidance on prevention,
                  diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2025;82:272-4. DOI PubMed
               7.  Vogel A, Chan SL, Dawson LA, et al. ; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Hepatocellular
                  carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36:491-506. DOI PubMed
               8.  Pinato DJ, Murray SM, Forner A, et al. Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in
                  hepatocellular carcinoma: implications for immunotherapy. J Immunother Cancer. 2021;9:e003311. DOI PubMed PMC
               9.  Tan J, Fan W, Liu T, et al. TREM2  macrophages suppress CD8  T-cell infiltration after transarterial chemoembolisation in
                                           +
                                                                +
                  hepatocellular carcinoma. J Hepatol. 2023;79:126-40. DOI PubMed
               10.  Wang Z, Li Q, Liang B. Hypoxia as a target for combination with transarterial chemoembolization in hepatocellular carcinoma.
                  Pharmaceuticals. 2024;17:1057. DOI PubMed PMC
               11.  Romero D. Early promising results with addition of an ICI and an anti-angiogenic to TACE. Nat Rev Clin Oncol. 2025;22:157. DOI
                  PubMed
               12.  Sangro B, Kudo M, Erinjeri JP, et al. ; EMERALD-1 Investigators. Durvalumab with or without bevacizumab with transarterial
                  chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3
                  study. Lancet. 2025;405:216-32. DOI PubMed PMC
               13.  Kudo M, Ren Z, Guo Y, et al. ; LEAP-012 investigators. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab
                  versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind,
                  phase 3 study. Lancet. 2025;405:203-15. DOI PubMed
               14.  Dong J, Han G, Ogasawara S, et al. LBA2 TALENTACE: a phase III, open-label, randomized study of on-demand transarterial
                  chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with
                  systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC). Ann Oncol. 2025;36:S62. DOI
               15.  Zhu H, Teng G, Fan W, et al. Transarterial chemoembolization (TACE) combined with camrelizumab and apatinib versus TACE alone
                  in the treatment of unresectable hepatocellular carcinoma eligible for embolization: a multicenter, open-label, randomized, phase 2 study
                  (CAP-ACE). JCO. 2025;43:LBA522. DOI
               16.  Zhou J, Sun H, Wang Z, et al. China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 Edition).
                  Liver Cancer. 2025;14:779-835. DOI PubMed PMC
               17.  Li C, Chen L, Bao H, Wang Y, Zhu G. Synergistic era: Practice and reflection on TACE combined with systemic therapy in
                  hepatocellular carcinoma. SciEriXiv. 2025. DOI
               18.  Matsui O, Kobayashi S, Sanada J, et al. Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT)
                  with special reference to multi-step hepatocarcinogenesis. Abdom Imaging. 2011;36:264-72. DOI PubMed PMC
               19.  Goldstein HM, Wallace S, Anderson JH, Bree RL, Gianturco C. Transcatheter occlusion of abdominal tumors. Radiology.
                  1976;120:539-45. DOI PubMed
               20.  Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology.
                  1989;170:783-6. DOI PubMed
               21.  Llovet JM, Real MI, Montaña X, et al. ; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic
                  treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-9. DOI PubMed
   62   63   64   65   66   67   68   69   70   71   72